Abstract
Aims: The aim of the study was to investigate the changes in quality of life (QoL) following transcatheter aortic valve implantation (TAVI) up to two years' follow-up. Methods and results: One hundred consecutive patients (46 females, mean age 79.7±6.1 years) with at least two years' follow-up who underwent TAVI in our institution, between November 2007 and September 2009, were enrolled in this study. Peak and mean aortic gradients were 87.8±25.8 mmHg and 53.3±15.4 mmHg, respectively. Mean log EuroSCORE was 27.9±15.9. Patients had multiple comorbidities. All patients underwent a standardised prospective screening pathway, including QoL evaluation with the 36-item short-form health survey (SF-36v2®) and the Minnesota Living with Heart Failure Questionnaires (MLHFQ). The scores obtained preoperatively were compared with those obtained at two years' follow-up. An Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA, USA) was implanted in 67 patients (55 transfemoral and 12 transapical) and a CoreValve (Medtronic, Inc., Minneapolis, MN, USA) was implanted in 33 patients (26 transfemoral and seven transaxillary). Thirty-day mortality was 4%. Actuarial survival was 80.6±4.1%, 72.6±4.7% and 63.2±6.3% at one, two and three years, respectively. Mean SF36-physical improved from 31.9±8.8 to 51.5±9.5 (p
| Original language | English |
|---|---|
| Pages (from-to) | 429-436 |
| Number of pages | 8 |
| Journal | EuroIntervention |
| Volume | 8 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Aug 2012 |
Fingerprint
Keywords
- Aortic stenosis
- Quality of life
- TAVI
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Quality of life improvement is maintained up to two years after transcatheter aortic valve implantation in high-risk surgical candidates. / Taramasso, Maurizio; Latib, Azeem; Cioni, Micaela; Denti, Paolo; Buzzatti, Nicola; Godino, Cosmo; Chieffo, Alaide; Alfieri, Ottavio; Colombo, Antonio; Maisano, Francesco.
In: EuroIntervention, Vol. 8, No. 4, 08.2012, p. 429-436.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Quality of life improvement is maintained up to two years after transcatheter aortic valve implantation in high-risk surgical candidates
AU - Taramasso, Maurizio
AU - Latib, Azeem
AU - Cioni, Micaela
AU - Denti, Paolo
AU - Buzzatti, Nicola
AU - Godino, Cosmo
AU - Chieffo, Alaide
AU - Alfieri, Ottavio
AU - Colombo, Antonio
AU - Maisano, Francesco
PY - 2012/8
Y1 - 2012/8
N2 - Aims: The aim of the study was to investigate the changes in quality of life (QoL) following transcatheter aortic valve implantation (TAVI) up to two years' follow-up. Methods and results: One hundred consecutive patients (46 females, mean age 79.7±6.1 years) with at least two years' follow-up who underwent TAVI in our institution, between November 2007 and September 2009, were enrolled in this study. Peak and mean aortic gradients were 87.8±25.8 mmHg and 53.3±15.4 mmHg, respectively. Mean log EuroSCORE was 27.9±15.9. Patients had multiple comorbidities. All patients underwent a standardised prospective screening pathway, including QoL evaluation with the 36-item short-form health survey (SF-36v2®) and the Minnesota Living with Heart Failure Questionnaires (MLHFQ). The scores obtained preoperatively were compared with those obtained at two years' follow-up. An Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA, USA) was implanted in 67 patients (55 transfemoral and 12 transapical) and a CoreValve (Medtronic, Inc., Minneapolis, MN, USA) was implanted in 33 patients (26 transfemoral and seven transaxillary). Thirty-day mortality was 4%. Actuarial survival was 80.6±4.1%, 72.6±4.7% and 63.2±6.3% at one, two and three years, respectively. Mean SF36-physical improved from 31.9±8.8 to 51.5±9.5 (p
AB - Aims: The aim of the study was to investigate the changes in quality of life (QoL) following transcatheter aortic valve implantation (TAVI) up to two years' follow-up. Methods and results: One hundred consecutive patients (46 females, mean age 79.7±6.1 years) with at least two years' follow-up who underwent TAVI in our institution, between November 2007 and September 2009, were enrolled in this study. Peak and mean aortic gradients were 87.8±25.8 mmHg and 53.3±15.4 mmHg, respectively. Mean log EuroSCORE was 27.9±15.9. Patients had multiple comorbidities. All patients underwent a standardised prospective screening pathway, including QoL evaluation with the 36-item short-form health survey (SF-36v2®) and the Minnesota Living with Heart Failure Questionnaires (MLHFQ). The scores obtained preoperatively were compared with those obtained at two years' follow-up. An Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA, USA) was implanted in 67 patients (55 transfemoral and 12 transapical) and a CoreValve (Medtronic, Inc., Minneapolis, MN, USA) was implanted in 33 patients (26 transfemoral and seven transaxillary). Thirty-day mortality was 4%. Actuarial survival was 80.6±4.1%, 72.6±4.7% and 63.2±6.3% at one, two and three years, respectively. Mean SF36-physical improved from 31.9±8.8 to 51.5±9.5 (p
KW - Aortic stenosis
KW - Quality of life
KW - TAVI
UR - http://www.scopus.com/inward/record.url?scp=84872068334&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872068334&partnerID=8YFLogxK
U2 - 10.4244/EIJV8I4A68
DO - 10.4244/EIJV8I4A68
M3 - Article
C2 - 22917725
AN - SCOPUS:84872068334
VL - 8
SP - 429
EP - 436
JO - EuroIntervention
JF - EuroIntervention
SN - 1774-024X
IS - 4
ER -